2026-06-16

Platinum volume spike — 8.7× the 20-day average (110 vs 12 avg)

Cocoa bull 9.0% vs prior close ($3,882.00 → $4,232.00)

WTI Crude Oil bear 6.1% vs prior close ($80.75 → $75.83)

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: BMW reporting alert raises concerns for German auto sector

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Oil -5.55% — significant selloff

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: UK Defense Spending Cuts Threaten Military Procurement

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Oil -4.66% — significant selloff

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: Iranian FM says US-Iran final agreement talks likely to begin Friday

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: US Oil Reserves Drop to 43-Year Low Amid Trump Price-Control Push

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Cotton bull 5.9% vs prior close ($73.43 → $77.76)

Sugar No. 11 bull 4.5% vs prior close ($13.68 → $14.29)

Silver volume spike — 2.2× the 20-day average (255 vs 115 avg)

Coffee bull 4.1% vs prior close ($262.95 → $273.60)

FDA approves SPINRAZA (BIOGEN) — new revenue stream

FDA approves SPINRAZA (BIOGEN) — new revenue stream

FDA approves SPINRAZA (BIOGEN) — new revenue stream

FDA approves KALETRA (AbbVie) — new revenue stream

FDA approves KALETRA (AbbVie) — new revenue stream

FDA approves KALETRA (AbbVie) — new revenue stream

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Phase 3 trial terminated early — JOHNSON A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the T

Phase 3 trial terminated early — JOHNSON A Study of Cisapride in Premature Infants With Feeding Problems

Phase 3 trial terminated early — JOHNSON Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment

Phase 3 trial terminated early — ELI A Long-Term Study in Schizophrenia

Phase 3 trial terminated early — ELI Duloxetine for the Treatment of Chronic Pelvic Pain

Phase 3 trial terminated early — ELI A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

Phase 3 trial terminated early — ELI A Study of Baricitinib (LY3009104) in Children With COVID-19

Phase 3 trial terminated early — ELI Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADH

Phase 3 trial terminated early — BRISTOL A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

Phase 3 trial terminated early — BRISTOL A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pe

FDA approves SOTYKTU (BRISTOL) — new revenue stream

Phase 3 trial terminated early — BIOGEN BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sc

Phase 3 trial terminated early — BIOGEN Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosi

Phase 3 trial terminated early — BIOGEN A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants

Phase 3 trial terminated early — BIOGEN 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase 3 trial terminated early — AMGEN A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as

Phase 3 trial terminated early — AMGEN STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Ou

Phase 3 trial terminated early — INCYTE A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopi

Phase 3 trial terminated early — INCYTE The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adu

Phase 3 trial terminated early — Medtronic BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Ther

Phase 3 trial terminated early — AbbVie Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natal

Phase 3 trial terminated early — Merck Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non

Phase 3 trial terminated early — Merck Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyper

Phase 3 trial terminated early — Merck An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Coliti

Phase 3 trial terminated early — PFIZER Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With

Phase 3 trial terminated early — PFIZER Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Di

Phase 3 trial terminated early — PFIZER Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-P

Phase 3 trial terminated early — PFIZER An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Rena

Phase 3 trial terminated early — PFIZER Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients

Phase 3 trial terminated early — PFIZER Extension Study Of Tanezumab In Osteoarthritis

Phase 3 trial terminated early — PFIZER Renal Allograft Function and Histology Following Switching From A Tacrolimus to

Phase 3 trial terminated early — ABBOTT LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Phase 3 trial terminated early — ABBOTT The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cart

Phase 3 trial terminated early — ABBOTT Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )

Phase 3 trial terminated early — GILEAD Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidin

Phase 3 trial terminated early — GILEAD Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Act

Phase 3 trial terminated early — GILEAD Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced C

Phase 3 trial terminated early — GILEAD DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Stud

Phase 3 trial terminated early — GILEAD Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of

Phase 3 trial terminated early — GILEAD Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (

Phase 3 trial terminated early — GILEAD Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardiovers

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

GE Vernova Inc. search volume spiked +100 pts — unusual interest

INTUITIVE SURGICAL INC search volume spiked +100 pts — unusual interest

LINDE PLC search volume spiked +100 pts — unusual interest

Q4-2025: Missed consensus by 25.8% — EPS $-0.29 vs $-0.2305 estimate

Q1-2026: Missed consensus by 595.8% — EPS $-0.78 vs $-0.1121 estimate

Q1-2020: Missed consensus by 88.1% — EPS $0.2 vs $1.6766 estimate

Q4-2019: Beat consensus by 241.0% — EPS $4.34 vs $1.2726 estimate

Q4-2024: Missed consensus by 296.3% — EPS $-791.835 vs $403.2991 estimate

Q3-2024: Beat consensus by 201.9% — EPS $3552.91 vs $1176.8008 estimate

Q1-2026: Beat consensus by 12.0% — EPS $0.38 vs $0.3392 estimate

Q4-2025: Beat consensus by 5.8% — EPS $0.31 vs $0.2929 estimate

Beat consensus by 7.9% — EPS $0.26 vs $0.241 estimate

Q2-2025: Missed consensus by 25.7% — EPS $0.25 vs $0.3366 estimate

Q3-2025: Beat consensus by 10.9% — EPS $0.43 vs $0.3876 estimate

Q2-2025: Beat consensus by 10.4% — EPS $1.302 vs $1.1797 estimate

Q3-2025: Missed consensus by 9.6% — EPS $0.93 vs $1.0288 estimate

Q1-2026: Beat consensus by 24.6% — EPS $1.15 vs $0.9229 estimate

Missed consensus by 23.7% — EPS $13.2 vs $17.304 estimate

Beat consensus by 253.0% — EPS $16 vs $4.532 estimate

Missed consensus by 51.0% — EPS $0.1 vs $0.204 estimate

Missed consensus by 30.7% — EPS $-0.4 vs $-0.306 estimate

Missed consensus by 197.6% — EPS $-168.35 vs $-56.56 estimate

Missed consensus by 61.5% — EPS $-21.7 vs $-13.433 estimate

Q1-2024: Missed consensus by 47.1% — EPS $-18.2 vs $-12.3725 estimate

Q1-2027: Beat consensus by 5.6% — EPS $0.14 vs $0.1326 estimate

Q1-2026: Beat consensus by 43.1% — EPS $0.26 vs $0.1817 estimate

Beat consensus by 18.1% — EPS $0.66 vs $0.559 estimate

Q1-2026: Beat consensus by 11.7% — EPS $0.3 vs $0.2686 estimate

Q4-2025: Missed consensus by 7.5% — EPS $0.61 vs $0.6592 estimate

Q2-2025: Beat consensus by 13.7% — EPS $0.67 vs $0.5893 estimate

Q3-2025: Beat consensus by 15.8% — EPS $0.61 vs $0.5266 estimate

Q2-2012: Beat consensus by 126.3% — EPS $20 vs $-76.1532 estimate

Q1-2012: Missed consensus by 134.2% — EPS $-180 vs $-76.8468 estimate

Beat consensus by 586.3% — EPS $140 vs $20.4 estimate

Missed consensus by 14.2% — EPS $140 vs $163.2 estimate

Missed consensus by 56.9% — EPS $-0.08 vs $-0.051 estimate

Q3-2025: Missed consensus by 929.4% — EPS $-0.21 vs $-0.0204 estimate

Q1-2026: Beat consensus by 34.6% — EPS $-0.04 vs $-0.0612 estimate

Q4-2025: Missed consensus by 138.1% — EPS $-0.17 vs $-0.0714 estimate

Q1-2026: Beat consensus by 9.5% — EPS $1.64 vs $1.4975 estimate

Q2-2025: Missed consensus by 7.6% — EPS $0.91 vs $0.9847 estimate

Q2-2025: Missed consensus by 14.4% — EPS $23.14 vs $27.0246 estimate

Q1-2026: Beat consensus by 66.0% — EPS $42.52 vs $25.6166 estimate

Q3-2025: Missed consensus by 161.9% — EPS $-9.96 vs $16.1024 estimate

Missed consensus by 354.1% — EPS $-28.11406 vs $11.062 estimate

Q1-2026: Beat consensus by 5.2% — EPS $0.22 vs $0.2091 estimate

Q4-2025: Beat consensus by 42.0% — EPS $0.25 vs $0.1761 estimate

Q1-2026: Missed consensus by 113.2% — EPS $-104.41 vs $-48.9668 estimate

Q4-2026: Beat consensus by 25.8% — EPS $737.77 vs $586.3999 estimate

Q3-2026: Beat consensus by 30.3% — EPS $524.42805 vs $402.4668 estimate

Q2-2026: Beat consensus by 183.1% — EPS $437.38079 vs $154.5037 estimate

Q2-2025: Missed consensus by 11.0% — EPS $0.62 vs $0.6963 estimate

Q1-2026: Beat consensus by 24.4% — EPS $0.85 vs $0.6831 estimate

Q3-2025: Missed consensus by 19.9% — EPS $0.54 vs $0.6738 estimate

Q3-2025: Beat consensus by 10.0% — EPS $1.37 vs $1.2452 estimate

Q2-2025: Beat consensus by 7.9% — EPS $1.26 vs $1.1675 estimate

Q3-2019: Missed consensus by 36.3% — EPS $0.45 vs $0.7066 estimate

Q2-2019: Beat consensus by 35.1% — EPS $0.93 vs $0.6882 estimate

Q4-2019: Missed consensus by 11.1% — EPS $0.3 vs $0.3376 estimate

Q1-2020: Missed consensus by 246.7% — EPS $-0.42 vs $0.2863 estimate

Missed consensus by 322.0% — EPS $-18.08 vs $-4.284 estimate

Beat consensus by 98.8% — EPS $-0.09 vs $-7.497 estimate

Missed consensus by 114.9% — EPS $-204.15 vs $-95.013 estimate

Missed consensus by 42.4% — EPS $-15.9 vs $-11.169 estimate

Beat consensus by 47.2% — EPS $-1.4 vs $-2.652 estimate

Missed consensus by 191.7% — EPS $-2.38 vs $-0.816 estimate

Missed consensus by 83.8% — EPS $-3 vs $-1.632 estimate

Q2-2026: Missed consensus by 96.1% — EPS $-0.02 vs $-0.0102 estimate

Q4-2025: Beat consensus by 296.1% — EPS $0.01 vs $-0.0051 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0051 estimate

Q2-2025: Beat consensus by 296.1% — EPS $0.02 vs $-0.0102 estimate

Missed consensus by 17.6% — EPS $-0.02 vs $-0.017 estimate

Missed consensus by 59.6% — EPS $-2.36 vs $-1.479 estimate

Q1-2026: Missed consensus by 366.9% — EPS $-1 vs $-0.2142 estimate

Q3-2025: Missed consensus by 86.9% — EPS $-0.61 vs $-0.3264 estimate

Q4-2025: Missed consensus by 416.1% — EPS $-1.79 vs $-0.3468 estimate

Q1-2026: Missed consensus by 7.0% — EPS $5.38 vs $5.7821 estimate

Q3-2025: Beat consensus by 24.3% — EPS $1.24 vs $0.9974 estimate

Q2-2025: Beat consensus by 12.7% — EPS $0.95 vs $0.8428 estimate

Q1-2026: Beat consensus by 16.0% — EPS $1.17 vs $1.0086 estimate

Q4-2025: Beat consensus by 5.1% — EPS $1.36 vs $1.2943 estimate

Q4-2025: Beat consensus by 10.9% — EPS $1.82 vs $1.6409 estimate

Q4-2025: Missed consensus by 5.9% — EPS $0.3 vs $0.3188 estimate

Q3-2025: Beat consensus by 5.4% — EPS $0.37 vs $0.3512 estimate

Q2-2026: Beat consensus by 21.6% — EPS $-0.004 vs $-0.0051 estimate

Q3-2026: Beat consensus by 80.2% — EPS $-0.01 vs $-0.0505 estimate

Q1-2026: Beat consensus by 70.3% — EPS $-0.003 vs $-0.0101 estimate

Q2-2025: Beat consensus by 240.9% — EPS $0.03 vs $0.0088 estimate

Q1-2026: Beat consensus by 210.3% — EPS $0.06 vs $-0.0544 estimate

Q4-2025: Beat consensus by 141.7% — EPS $0.08 vs $0.0331 estimate

Q4-2025: Missed consensus by 347.0% — EPS $-0.27 vs $-0.0604 estimate

Q3-2025: Missed consensus by 175.2% — EPS $-0.12 vs $-0.0436 estimate

Q2-2025: Beat consensus by 6.2% — EPS $-0.05 vs $-0.0533 estimate

Q4-2025: Missed consensus by 63.4% — EPS $-0.05 vs $-0.0306 estimate

Q2-2025: Beat consensus by 73.9% — EPS $-0.02 vs $-0.0765 estimate

Q3-2025: Missed consensus by 466.4% — EPS $-0.26 vs $-0.0459 estimate

Q1-2025: Beat consensus by 30.0% — EPS $-0.05 vs $-0.0714 estimate

Q1-2026: Beat consensus by 40.0% — EPS $0.19 vs $0.1357 estimate

Q4-2025: Beat consensus by 98.7% — EPS $0.37 vs $0.1862 estimate

BTC ETF outflow of $3013M — institutional selling

ETH ETF outflow of $784M — institutional selling

ETH open interest -66.5% — OI collapse

BTC open interest -40.8% — OI collapse

SOL open interest -32.0% — OI collapse

ETH open interest +216.8% — OI surge

BTC open interest -39.9% — OI collapse

SOL open interest +292.8% — OI surge

SPYx/USDC has $31.0M volume but only $578K liquidity — thin market, slippage risk

SOL open interest +293.7% — OI surge

BTC open interest +233.8% — OI surge

ETH open interest +211.8% — OI surge